Oxford-based SynaptixBio  has been awarded a £2 million BioMedical Catalyst grant from Innovate UK to support first-in-human clinical trials of the company’s leukodystrophy treatment targeting H-ABC, the most severe form of TUBB4A leukodystrophy. TUBB4A-related leukodystrophies are a group of rare neurodegenerative diseases primarily affecting young children. They are caused by mutations in the TUBB4A gene, […]